• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清蛋白和粪便微生物群作为新诊断的、未接受过治疗的炎症性肠病和肠易激综合征患者的潜在生物标志物。

Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients.

作者信息

Matijašić Mario, Barešić Anja, Čipčić Paljetak Hana, Perić Mihaela, Panek Marina, Kunović Ana, Ljubas Kelečić Dina, Vranešić Bender Darija, Grubelić Ravić Katja, Rogić Dunja, Antolic Margareta, Horvat Ivana, Kraljević Ivana, Banić Marko, Krznarić Željko, Verbanac Donatella

机构信息

Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.

Laboratory for Computational Biology and Translational Medicine , Ruđer Bošković Institute, Zagreb, Croatia.

出版信息

J Mol Med (Berl). 2025 Jun 7. doi: 10.1007/s00109-025-02558-5.

DOI:10.1007/s00109-025-02558-5
PMID:40481885
Abstract

Molecular biomarkers are valuable tools to predict the disease and determine its course. Several markers have been associated with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS); however, none is sufficiently reliable to enable accurate diagnosis. We characterized a broad panel of serum proteins to assess disease-specific biomarker profiles and associate these findings with faecal microbiota composition in newly diagnosed IBD and IBS patients and healthy individuals. The study cohort consisted of 49 newly diagnosed treatment-naïve adult patients (13 Crohn's disease (CD), 13 ulcerative colitis (UC), and 23 IBS) and 12 healthy individuals. Inflammatory and metabolism-related serum proteins were assessed using PEA multiplex panels, while gut microbiota composition was determined by 16 s rRNA gene amplicon sequencing. Serum proteins AXIN1, TNFSF14, RNASE3, EN-RAGE, OSM, ST1A1, CA13 and NADK were identified as markers with the most promising specificity/sensitivity and predictivity between healthy and disease groups, while IL-17A and TNFRSF9 enabled differentiation between IBD and IBS patients. Increased abundance of Enterobacteriaceae was associated with protein markers significantly elevated in IBD/IBS. In contrast, depletion of beneficial taxa like Ruminococcaceae and Verucomicrobiaceae (i.e. Akkermansia muciniphila) was associated with decrease of a set of markers in diseased groups. Differences in the abundance of Turicibacteriaceae were more predictive to discern CD from UC than any of the serum proteins investigated. By using a broad panel of inflammation and metabolism-related proteins, we determined serum markers with significantly different levels in treatment-naïve IBD and IBS patients compared to healthy individuals, as well as between IBD and IBS. KEY MESSAGES : Significant changes in the levels of several serum proteins and abundances of faecal bacterial taxa between study groups were found. Increased levels of AXIN1, TNFSF14, RNASE3, EN-RAGE, OSM, ST1A1, CA13 and NADK characterize both IBD and IBS, while IL-17A and TNFRSF9 differentiate IBD from IBS. Increase of Enterobacteriaceae and depletion of beneficial taxa Ruminococcaceae and Verucomicrobiaceae (i.e. Akkermansia muciniphila) was found in IBD and IBS. Differences in Turicibacteriaceae were more predictive to discern CD from UC than any of the serum proteins investigated.

摘要

分子生物标志物是预测疾病和确定其病程的宝贵工具。几种标志物已与炎症性肠病(IBD)和肠易激综合征(IBS)相关联;然而,没有一种标志物足够可靠到能够进行准确诊断。我们对一组广泛的血清蛋白进行了特征分析,以评估疾病特异性生物标志物谱,并将这些发现与新诊断的IBD和IBS患者以及健康个体的粪便微生物群组成相关联。研究队列包括49名新诊断的未接受过治疗的成年患者(13例克罗恩病(CD)、13例溃疡性结肠炎(UC)和23例IBS)以及12名健康个体。使用PEA多重检测板评估炎症和代谢相关的血清蛋白,同时通过16s rRNA基因扩增子测序确定肠道微生物群组成。血清蛋白AXIN1、TNFSF14、RNASE3、EN-RAGE、OSM、ST1A1、CA13和NADK被鉴定为在健康组和疾病组之间具有最有前景的特异性/敏感性和预测性的标志物,而IL-17A和TNFRSF9能够区分IBD和IBS患者。肠杆菌科丰度的增加与IBD/IBS中显著升高的蛋白标志物相关。相反,有益菌属如瘤胃球菌科和疣微菌科(即嗜黏蛋白阿克曼氏菌)的减少与疾病组中一组标志物的减少相关。Turicibacteriaceae丰度的差异比所研究的任何血清蛋白更能预测区分CD和UC。通过使用一组广泛的炎症和代谢相关蛋白,我们确定了与健康个体相比,未接受过治疗的IBD和IBS患者以及IBD和IBS之间水平有显著差异的血清标志物。关键信息:研究组之间发现了几种血清蛋白水平和粪便细菌类群丰度的显著变化。AXIN1、TNFSF14、RNASE3、EN-RAGE,、OSM、ST1A1、CA13和NADK水平的升高是IBD和IBS的特征,而IL-17A和TNFRSF9可区分IBD和IBS。在IBD和IBS中发现肠杆菌科增加以及有益菌属瘤胃球菌科和疣微菌科(即嗜黏蛋白阿克曼氏菌)减少。Turicibacteriaceae的差异比所研究的任何血清蛋白更能预测区分CD和UC。

相似文献

1
Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients.血清蛋白和粪便微生物群作为新诊断的、未接受过治疗的炎症性肠病和肠易激综合征患者的潜在生物标志物。
J Mol Med (Berl). 2025 Jun 7. doi: 10.1007/s00109-025-02558-5.
2
Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.粪便钙卫蛋白检测在鉴别炎症性和非炎症性肠病中的应用:系统评价和经济评估。
Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211. doi: 10.3310/hta17550.
3
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.使用鸟枪法宏基因组学对新诊断的炎症性肠病患者的粪便微生物群进行探索。
Front Cell Infect Microbiol. 2025 Jul 1;15:1595884. doi: 10.3389/fcimb.2025.1595884. eCollection 2025.
4
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey.中重度溃疡性结肠炎和克罗恩病对性活动的影响:来自炎症性肠病经历的沟通需求与特征(CONFIDE)调查的美国和欧洲患者观点
Curr Med Res Opin. 2025 Jul 17:1-14. doi: 10.1080/03007995.2025.2530736.
5
[1]The human gut microbiota in IBD, characterizing hubs, the core microbiota and terminal nodes: a network-based approach.[1]炎症性肠病中的人体肠道微生物群,表征枢纽、核心微生物群和终端节点:一种基于网络的方法。
BMC Microbiol. 2025 Jun 26;25(1):371. doi: 10.1186/s12866-025-04106-0.
6
[Characteristics and clinical significance of neutrophil extracellular traps in children with inflammatory bowel disease].[炎症性肠病患儿中性粒细胞胞外诱捕网的特征及临床意义]
Zhonghua Er Ke Za Zhi. 2025 Jul 2;63(7):759-764. doi: 10.3760/cma.j.cn112140-20241217-00922.
7
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.肠道生物标志物、微生物群组成以及炎症性肠病的遗传易感性作为帕金森病表现的预测指标。
J Parkinsons Dis. 2025 May 7:1877718X251328567. doi: 10.1177/1877718X251328567.
8
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.
9
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
10
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.

本文引用的文献

1
Gut Dysbiosis in Irritable Bowel Syndrome: A Narrative Review on Correlation with Disease Subtypes and Novel Therapeutic Implications.肠易激综合征中的肠道菌群失调:关于与疾病亚型的相关性及新治疗意义的叙述性综述
Microorganisms. 2023 Sep 22;11(10):2369. doi: 10.3390/microorganisms11102369.
2
SNAP23 decreases insulin secretion by competitively inhibiting the interaction between SNAP25 and STX1A.突触融合蛋白 23(SNAP23)通过竞争性抑制突触融合蛋白 25(SNAP25)和 STX1A 之间的相互作用来降低胰岛素分泌。
Biosci Rep. 2023 May 31;43(5). doi: 10.1042/BSR20222594.
3
Bidirectional Mendelian Randomisation Analysis Provides Evidence for the Causal Involvement of Dysregulation of CXCL9, CCL11 and CASP8 in the Pathogenesis of Ulcerative Colitis.
双向孟德尔随机化分析为 CXCL9、CCL11 和 CASP8 失调在溃疡性结肠炎发病机制中的因果关系提供了证据。
J Crohns Colitis. 2023 May 3;17(5):777-785. doi: 10.1093/ecco-jcc/jjac191.
4
The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease.炎症性肠病分子生物标志物的现状
Biomedicines. 2022 Jun 24;10(7):1492. doi: 10.3390/biomedicines10071492.
5
Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients.新诊断、未经治疗的成人炎症性肠病和肠易激综合征患者的黏膜和粪便中的肠道微生物群。
Gut Microbes. 2022 Jan-Dec;14(1):2083419. doi: 10.1080/19490976.2022.2083419.
6
Human gut bacterial metabolism drives Th17 activation and colitis.人体肠道细菌代谢物驱动 Th17 细胞激活并引发结肠炎。
Cell Host Microbe. 2022 Jan 12;30(1):17-30.e9. doi: 10.1016/j.chom.2021.11.001. Epub 2021 Nov 24.
7
Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies.Th17 细胞在炎症性肠病中的作用:细胞因子、可塑性和治疗方法。
J Immunol Res. 2021 Jan 22;2021:8816041. doi: 10.1155/2021/8816041. eCollection 2021.
8
Galanin receptor 3 attenuates inflammation and influences the gut microbiota in an experimental murine colitis model.甘丙肽受体 3 可减轻实验性结肠炎模型中的炎症反应并影响肠道微生物群。
Sci Rep. 2021 Jan 12;11(1):564. doi: 10.1038/s41598-020-79456-y.
9
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.在炎症性肠病诊断时的血清蛋白质组谱分析可预测临床病程和治疗强化的需要。
J Crohns Colitis. 2021 May 4;15(5):699-708. doi: 10.1093/ecco-jcc/jjaa230.
10
Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines.炎症性肠病中的线粒体功能障碍改变了肠道上皮细胞对肝脏酰基辅酶 A 的代谢。
J Clin Invest. 2021 Jan 4;131(1). doi: 10.1172/JCI133371.